

## Answer to the letter Lung vascular disorders in liver transplant tertiary referral centers in Mexico

Laura E. Cisneros-Garza

\* Departamento de Gastroenterología y Hepatología, Unidad Médica de Alta Especialidad Núm. 25, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León.

## The author's reply:

We thank Dr. Mateo Porres-Aguilar, et al. for their interesting remarks concerning our study and appreciate their valuable suggestions about the screening of lung vascular disorders in all patients on the waiting list for liver transplantation. We are a multidisciplinary team (hepatologists, surgeons, cardiologists, pulmonologists, critical care specialists, anesthesiologists), and have evaluation protocols in agreement with the practice guidelines of the American Association for the Study of Liver Diseases.<sup>2</sup> Portopulmonary hypertension (POPH) is a well recognized risk factor that can adversely affect the outcome of ortothopic liver transplantation and it is related to the severity of the condition.<sup>3,4</sup> Hepatologists should consider this complication even in the abscense of clinical manifestations and should also evaluate each patient in order to discard this pathology before including them in the waiting list.<sup>5</sup> All patients in our center undergo a cardiac and pulmonary evaluation and also a screening for POPH. Invasive cardiologists are actively involved and are aware of this particular condition. In addition to physical examination, chest radiography, electrocardiogram, arterial blood gas measurements and pulfunction testing a transthoracic monary echocardiography with Doppler estimation of pulmonary artery systolic pressure (PASP) is used as a screening tool and a cut off of 40 mmHg to identify candidates for right heart catheterization is used.<sup>6-8</sup> We would like to mention that from all of the patients included in the cardiovascular risk factors

analysis 15 of them (57.6%) had their transplantation done in other different centers. Two of this patients had tricuspid insuficiency, one of them belonged to a different hospital and the other was from ours. All our patients had PSAP (< 40 mmHg), and no signs of right ventricular hypertrophy or dilatation. We know that the abscense of PPH at the time of the evaluation does not exclude the ocassional ocurrence of POPH after listing. The timing in our waiting list is in average from 8 to 12 months so, we evaluate them every six months.

## REFERENCES

- Cisneros G LE, López H PA, Muñoz R MR, Castilla V MP, Sebastian R MJ, Alvarez TGA, et al. Trasplante Hepático en la Unidad Médica de Alta Especialidad No. 25, IMSS Monterrery. Rev Invest Clin 2011; 63 (Suppl. 1): 67-72.
- Murray KF, Carithers RL. AASLD Practice Guidelines: Evaluation of the Patient for Liver Transplantation. *Hepatology* 2005; 41(6): 1407-31.
- Simonneau G, Nazzareno G, Rubin LG, Langleben D, Seeger W. Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiology 2004; 43: 5S-12S.
- 4. Krowka MK. Portopulmonary Hypertension. Semin Respir Critical Care Med 2012; 33: 17-25.
- Saballe L, O'Callaghan DS, Magnier R, Le Pavec J, Hervé P, et al. Current management approaches to portopulmonary hypertension. *Int Journal of Clinical Practice* 2011; 65 (Suppl. 169): 11-18
- Colle I, Moreau R, Godinho E, Belghiti J. Errori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 2003; 2: 401-9.
- Cotton CL, Gandhi S, Vaitkus PT, Massad MG, Benedetti E, Mrtek RG, Wiley TE. Role of echocardiography in detecting portopulmonaty hypertension in liver transplant candidates. *Liver Transpl* 2002; 8: 1051-54.

- 8. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, Wiesner RH. Accuracy of Doppler Echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. *Liver Transpl* 2000; 6: 453-8.
- 9. Mukhtar NA, Fix OK. Portopulmonary Hypertension. *J Clin Gastroenterol* 2011; 45: 703-10.

Reimpresos:

Dra. Laura E. Cisneros-Garza

Unidad Médica de Alta Especialidad Núm. 25, IMSS Monterrey N.L.

Lincon y Gonzalitos s/n

Col. Morelos

64320, Monterrey N.L. Tel.: (+52 81) 8371-2031 Fax: (+52 81) 8371-2344

Correo electrónico: laura\_cisneros@yahoo.com

Recibido el 2 de octubre de 2012. Aceptado el 15 de octubre de 2012.